SEQSTER CEO Ardy Arianpour on AWS Bio Discovery, fragmented health records and AI drug discovery’s missing patient layer
Brian Buntz
Big Tech is sharpening its focus on healthcare and drug development. Amazon’s recent Bio Discovery launch is one recent signal, with AWS pushing into agentic AI application for antibody design. It joins a growing playing field: Google DeepMind’s Isomorphic Labs has advanced pharma partnerships with Novartis and Eli Lilly on the back of AlphaFold 3… The post SEQSTER CEO Ardy Arianpour on AWS Bio Discovery, fragmented health records and AI drug discovery’s missing patient layer appeared first on R